

Swati Nagar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8458240/publications.pdf>

Version: 2024-02-01

43
papers

953
citations

516710

16
h-index

454955

30
g-index

44
all docs

44
docs citations

44
times ranked

1200
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting impact of food and feeding time on oral absorption of drugs with a novel rat continuous intestinal absorption model. Drug Metabolism and Disposition, 2022, , DMD-AR-2022-000831.	3.3	1
2	Using Partition Analysis as a Facile Method to Derive Net Clearances. Clinical and Translational Science, 2022, , .	3.1	2
3	A Permeability- and Perfusion- based PBPK model for Improved Prediction of Concentration-time Profiles. Clinical and Translational Science, 2022, , .	3.1	4
4	Case Study 2: Practical Analytical Considerations for Conducting In Vitro Enzyme Kinetic Studies. Methods in Molecular Biology, 2021, 2342, 643-652.	0.9	0
5	Numerical Methods for Modeling Enzyme Kinetics. Methods in Molecular Biology, 2021, 2342, 147-168.	0.9	3
6	Complex Cytochrome P450 kinetics due to multisubstrate binding and sequential metabolism. Part 2. Modeling of experimental data. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2021-000554.	3.3	4
7	Complex Cytochrome P450 kinetics due to multisubstrate binding and sequential metabolism. Part 1. Theoretical considerations.. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2021-000553.	3.3	1
8	Numerical analysis of time-dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting. Xenobiotica, 2020, 50, 1301-1310.	1.1	4
9	A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats. Xenobiotica, 2020, 50, 536-544.	1.1	5
10	Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. , 2020, 206, 107449.		21
11	Numerical method analysis of the activation and time-dependent inhibition of midazolam metabolism by ticlopidine. FASEB Journal, 2020, 34, 1-1.	0.5	0
12	Methods to Predict Volume of Distribution. Current Pharmacology Reports, 2019, 5, 391-399.	3.0	7
13	Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation. Drug Metabolism and Disposition, 2019, 47, 732-742.	3.3	6
14	Prediction of Tissue-Plasma Partition Coefficients Using Microsomal Partitioning: Incorporation into Physiologically based Pharmacokinetic Models and Steady-State Volume of Distribution Predictions. Drug Metabolism and Disposition, 2019, 47, 1050-1060.	3.3	17
15	Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A. Molecular Pharmaceutics, 2018, 15, 1979-1995.	4.6	26
16	Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clinical Pharmacology and Therapeutics, 2018, 104, 865-889.	4.7	92
17	Improved Prediction Of Clinical Drug-Drug Interactions Using A Novel Numerical Method For Evaluation Of Time-Dependent Inhibition Of Cytochrome P450. FASEB Journal, 2018, 32, 834.9.	0.5	0
18	Drug Distribution. Part 1. Models to Predict Membrane Partitioning. Pharmaceutical Research, 2017, 34, 535-543.	3.5	12

#	ARTICLE	IF	CITATIONS
19	Drug Distribution Part 2. Predicting Volume of Distribution from Plasma Protein Binding and Membrane Partitioning. <i>Pharmaceutical Research</i> , 2017, 34, 544-551.	3.5	22
20	On the Nature of Physiologically-Based Pharmacokinetic Models – A Priori or A Posteriori? Mechanistic or Empirical?. <i>Pharmaceutical Research</i> , 2017, 34, 529-534.	3.5	15
21	Continuous Intestinal Absorption Model Based on the Convection–Diffusion Equation. <i>Molecular Pharmaceutics</i> , 2017, 14, 3069-3086.	4.6	12
22	A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 123-141.	1.9	32
23	Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 26-36.	2.5	14
24	Mechanism-Based Inhibition of CYP3A4 by Podophyllotoxin: Aging of an Intermediate Is Important for in Vitro/in Vivo Correlations. <i>Molecular Pharmaceutics</i> , 2016, 13, 2833-2843.	4.6	19
25	A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 1. Theoretical Considerations. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1575-1586.	3.3	25
26	Herb–Drug Interactions: Challenges and Opportunities for Improved Predictions. <i>Drug Metabolism and Disposition</i> , 2014, 42, 301-317.	3.3	148
27	Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. <i>Xenobiotica</i> , 2014, 44, 792-803.	1.1	5
28	A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1587-1595.	3.3	22
29	Compartmental Models for Apical Efflux by P-glycoprotein: Part 2 – A Theoretical Study on Transporter Kinetic Parameters. <i>Pharmaceutical Research</i> , 2014, 31, 335-346.	3.5	17
30	Compartmental Models for Apical Efflux by P-glycoprotein – Part 1: Evaluation of Model Complexity. <i>Pharmaceutical Research</i> , 2014, 31, 347-359.	3.5	21
31	Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications. <i>Methods in Molecular Biology</i> , 2014, 1113, 1-6.	0.9	31
32	Case Study 2. Practical Analytical Considerations for Conducting In Vitro Enzyme Kinetic Studies. <i>Methods in Molecular Biology</i> , 2014, 1113, 431-439.	0.9	2
33	Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC–ESI-MS/MS. <i>Xenobiotica</i> , 2013, 43, 1073-1083.	1.1	5
34	Pharmacokinetic application of a bioanalytical LC–MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. <i>Biomedical Chromatography</i> , 2013, 27, 994-1002.	1.7	14
35	Models to Predict Unbound Intracellular Drug Concentrations in the Presence of Transporters. <i>Drug Metabolism and Disposition</i> , 2012, 40, 865-876.	3.3	50
36	Commentary: Nonspecific Protein Binding versus Membrane Partitioning: It Is Not Just Semantics. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1649-1652.	3.3	57

#	ARTICLE	IF	CITATIONS
37	In Vivo-Formed versus Preformed Metabolite Kinetics of <i>trans</i> -Resveratrol-3-sulfate and <i>trans</i> -Resveratrol-3-glucuronide. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1993-2001.	3.3	16
38	Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 124-132.	1.6	16
39	Role of pharmacogenetics in variable response to drugs: focus on opioids. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 77-91.	3.3	58
40	Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 879-894.	3.3	22
41	Looking beyond the administered drug: metabolites of opioid analgesics. <i>Journal of Family Practice</i> , 2008, 57, S25-32.	0.2	2
42	Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan. <i>Drug Metabolism Reviews</i> , 2006, 38, 393-409.	3.6	102
43	Conjugative Metabolism of Drugs. , 0, , 37-88.		7